🚀 VC round data is live in beta, check it out!
Jubilant Pharmova Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jubilant Pharmova and similar public comparables like ORIC Pharmaceuticals, Chongqing Genrix, Iovance Biotherapeutics, Tango Therapeutics and more.
Jubilant Pharmova Overview
About Jubilant Pharmova
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
Founded
1978
HQ
Employees
978
Website
Financials (LTM)
EV
$2B
Jubilant Pharmova Financials
Jubilant Pharmova reported last 12-month revenue of $873M and EBITDA of $134M.
In the same LTM period, Jubilant Pharmova generated $591M in gross profit, $134M in EBITDA, and $47M in net income.
Revenue (LTM)
Jubilant Pharmova P&L
In the most recent fiscal year, Jubilant Pharmova reported revenue of $846M and EBITDA of $169M.
Jubilant Pharmova expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $873M | XXX | $846M | XXX | XXX | XXX |
| Gross Profit | $591M | XXX | $493M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $134M | XXX | $169M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $47M | XXX | $90M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | — | — | $145M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jubilant Pharmova Stock Performance
Jubilant Pharmova has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Jubilant Pharmova's stock price is $9.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.2% | XXX | XXX | XXX | $0.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJubilant Pharmova Valuation Multiples
Jubilant Pharmova trades at 2.0x EV/Revenue multiple, and 13.0x EV/EBITDA.
EV / Revenue (LTM)
Jubilant Pharmova Financial Valuation Multiples
As of April 8, 2026, Jubilant Pharmova has market cap of $2B and EV of $2B.
Equity research analysts estimate Jubilant Pharmova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jubilant Pharmova has a P/E ratio of 32.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBIT | 20.2x | XXX | 18.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.5x | XXX | XXX | XXX |
| P/E | 32.3x | XXX | 16.8x | XXX | XXX | XXX |
| EV/FCF | (52.1x) | XXX | 56.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jubilant Pharmova Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jubilant Pharmova Margins & Growth Rates
Jubilant Pharmova's revenue in the last 12 month grew by 13%.
Jubilant Pharmova's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.4M for the same period.
Jubilant Pharmova's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jubilant Pharmova's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jubilant Pharmova Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | (21%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jubilant Pharmova Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ORIC Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Chongqing Genrix | XXX | XXX | XXX | XXX | XXX | XXX |
| Iovance Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tango Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corvus Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jubilant Pharmova M&A Activity
Jubilant Pharmova acquired XXX companies to date.
Last acquisition by Jubilant Pharmova was on XXXXXXXX, XXXXX. Jubilant Pharmova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jubilant Pharmova
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJubilant Pharmova Investment Activity
Jubilant Pharmova invested in XXX companies to date.
Jubilant Pharmova made its latest investment on XXXXXXXX, XXXXX. Jubilant Pharmova invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jubilant Pharmova
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jubilant Pharmova
| When was Jubilant Pharmova founded? | Jubilant Pharmova was founded in 1978. |
| Where is Jubilant Pharmova headquartered? | Jubilant Pharmova is headquartered in India. |
| How many employees does Jubilant Pharmova have? | As of today, Jubilant Pharmova has over 978 employees. |
| Is Jubilant Pharmova publicly listed? | Yes, Jubilant Pharmova is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Jubilant Pharmova? | Jubilant Pharmova trades under JUBLPHARMA ticker. |
| When did Jubilant Pharmova go public? | Jubilant Pharmova went public in 2003. |
| Who are competitors of Jubilant Pharmova? | Jubilant Pharmova main competitors are ORIC Pharmaceuticals, Chongqing Genrix, Iovance Biotherapeutics, Tango Therapeutics. |
| What is the current market cap of Jubilant Pharmova? | Jubilant Pharmova's current market cap is $2B. |
| What is the current revenue of Jubilant Pharmova? | Jubilant Pharmova's last 12 months revenue is $873M. |
| What is the current revenue growth of Jubilant Pharmova? | Jubilant Pharmova revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Jubilant Pharmova? | Current revenue multiple of Jubilant Pharmova is 2.0x. |
| Is Jubilant Pharmova profitable? | Yes, Jubilant Pharmova is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jubilant Pharmova? | Jubilant Pharmova's last 12 months EBITDA is $134M. |
| What is Jubilant Pharmova's EBITDA margin? | Jubilant Pharmova's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Jubilant Pharmova? | Current EBITDA multiple of Jubilant Pharmova is 13.0x. |
| What is the current FCF of Jubilant Pharmova? | Jubilant Pharmova's last 12 months FCF is ($33M). |
| What is Jubilant Pharmova's FCF margin? | Jubilant Pharmova's last 12 months FCF margin is (4%). |
| What is the current EV/FCF multiple of Jubilant Pharmova? | Current FCF multiple of Jubilant Pharmova is (52.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.